BR112017006420A2 - derivados de ácido borônico - Google Patents

derivados de ácido borônico

Info

Publication number
BR112017006420A2
BR112017006420A2 BR112017006420A BR112017006420A BR112017006420A2 BR 112017006420 A2 BR112017006420 A2 BR 112017006420A2 BR 112017006420 A BR112017006420 A BR 112017006420A BR 112017006420 A BR112017006420 A BR 112017006420A BR 112017006420 A2 BR112017006420 A2 BR 112017006420A2
Authority
BR
Brazil
Prior art keywords
acid derivatives
boronic acid
anomaly
employed
compounds
Prior art date
Application number
BR112017006420A
Other languages
English (en)
Inventor
Klein Markus
Busch Michael
Schadt Oliver
Haselmayer Philipp
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112017006420A2 publication Critical patent/BR112017006420A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

os compostos de fórmula (i) são inibidores de lmp7 e podem ser empregados, inter alia, para o tratamento de uma anomalia de doença autoimune ou malignidades hematológicas.
BR112017006420A 2014-10-01 2015-10-01 derivados de ácido borônico BR112017006420A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14003392 2014-10-01
PCT/EP2015/002008 WO2016050359A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (1)

Publication Number Publication Date
BR112017006420A2 true BR112017006420A2 (pt) 2017-12-19

Family

ID=51690789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006420A BR112017006420A2 (pt) 2014-10-01 2015-10-01 derivados de ácido borônico

Country Status (14)

Country Link
US (1) US10294246B2 (pt)
EP (1) EP3201207B1 (pt)
JP (1) JP6835711B2 (pt)
KR (1) KR102450583B1 (pt)
CN (1) CN107001390B (pt)
AU (1) AU2015327346B2 (pt)
BR (1) BR112017006420A2 (pt)
CA (1) CA2963205A1 (pt)
ES (1) ES2873000T3 (pt)
IL (1) IL251301B (pt)
MX (1) MX370336B (pt)
RU (1) RU2017115188A (pt)
SG (1) SG11201702623TA (pt)
WO (1) WO2016050359A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717558C2 (ru) 2014-10-01 2020-03-24 Мерк Патент Гмбх Производные бороновой кислоты
WO2016050355A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
US10253049B2 (en) 2014-10-01 2019-04-09 Merck Patent Gmbh Boronic acid derivatives
PT3672977T (pt) * 2017-08-24 2022-09-23 Merck Patent Gmbh Derivados do ácido borónico
JP2021531310A (ja) 2018-07-26 2021-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
IL310390A (en) 2021-07-29 2024-03-01 Merck Patent Gmbh Crystalline forms of [(R1)-2-benzofuran-3-yl)-1-{[(R4, R2, S1)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, Their adducts and their use
WO2023061445A1 (zh) * 2021-10-14 2023-04-20 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
CA2376965A1 (en) * 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AR069310A1 (es) * 2007-11-13 2010-01-13 Protez Pharmaceuticals Inc Inhibidores de beta- lactamasa
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
BR112014015363A2 (pt) * 2011-12-22 2017-06-13 Ares Trading Sa derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
RU2717558C2 (ru) 2014-10-01 2020-03-24 Мерк Патент Гмбх Производные бороновой кислоты
WO2016050355A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
US10253049B2 (en) 2014-10-01 2019-04-09 Merck Patent Gmbh Boronic acid derivatives

Also Published As

Publication number Publication date
JP6835711B2 (ja) 2021-02-24
CA2963205A1 (en) 2016-04-07
RU2017115188A (ru) 2018-11-06
IL251301A0 (en) 2017-05-29
AU2015327346B2 (en) 2019-12-05
AU2015327346A1 (en) 2017-05-18
RU2017115188A3 (pt) 2019-03-29
CN107001390B (zh) 2020-11-27
JP2017536335A (ja) 2017-12-07
MX2017004046A (es) 2017-06-19
KR102450583B1 (ko) 2022-10-04
CN107001390A (zh) 2017-08-01
EP3201207A1 (en) 2017-08-09
WO2016050359A1 (en) 2016-04-07
KR20170062517A (ko) 2017-06-07
US10294246B2 (en) 2019-05-21
MX370336B (es) 2019-12-10
ES2873000T3 (es) 2021-11-03
IL251301B (en) 2022-02-01
US20180105539A1 (en) 2018-04-19
EP3201207B1 (en) 2021-02-24
SG11201702623TA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
BR112017006420A2 (pt) derivados de ácido borônico
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
PH12017500293A1 (en) Boronic acid derivatives
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
BR112017006349A2 (pt) derivados de ácido borônico
BR112017006368A2 (pt) derivados de ácido borônico
BR112019003914A2 (pt) inibidores de processos metabólicos celulares
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
BR112017024555A2 (pt) moduladores de ccr2
EA201891526A2 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
NZ730603A (en) Mk2 inhibitors and uses thereof
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time